SaiLong Pharma Group Co., Ltd. 2025 Annual Independent Director Performance Report (Zhang Jianmin)
From August 26, 2025, I was appointed as an independent director of SaiLong Pharma Group Co., Ltd. (hereinafter referred to as the "Company"). During my term in 2025, I strictly adhered to the "Company Law," the "Administrative Measures for Independent Directors of Listed Companies," and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 1 - Norms for Operations of Main Board Listed Companies," among other relevant regulations. I leveraged my professional expertise to actively follow and participate in the research of the Company's development, fulfilling my duties objectively, fairly, and independently, fully exercising the role of an independent director, and safeguarding the overall interests of the Company and the legitimate rights and interests of all shareholders, especially small and medium shareholders.
Here is my performance report for the term in 2025:
I. Independence Status
During my term in 2025, my position complied with the independence requirements for independent directors as stipulated in the "Administrative Measures for Independent Directors of Listed Companies" and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 1 - Norms for Operations of Main Board Listed Companies." There were no circumstances affecting my independence.
II. Annual Performance
(I) Attendance at Board and Shareholder Meetings
Since I took office as an independent director of the Company on August 26, 2025, a total of 9 board meetings have been held. I attended all meetings, voted on all deliberation items, and signed the board resolutions. There were no instances of entrusting attendance or absence from meetings.
Since I took office as an independent director of the Company on August 26, 2025, a total of 3 shareholder meetings have been held. I attended all meetings.
(II) Participation in Board Special Committees and Independent Director Special Meetings
During the reporting period, I attended 1 meeting of the Nomination Committee, 2 meetings of the Fourth Board of Directors' Independent Director Special Committee, and attended 4 meetings of the Board of Directors' Audit Committee as an attendee.
(III) Exercise of Independent Director Powers
I attended the third and fourth meetings of the Fourth Board of Directors' Independent Director Special Committee in 2025. The meetings deliberated and approved the "Proposal on the Company's Subsidiary Applying for a Comprehensive Credit Line and Providing Guarantees" and the "Proposal on the Company Applying for a Comprehensive Credit Line and Accepting Guarantees from its Wholly-Owned Subsidiary," and I issued an opinion of approval.
As the Chairman of the Remuneration and Nomination Committee, I convened a special meeting to investigate the issue of "non-standard remuneration management procedures for directors and senior management" mentioned in the "Letter of Concern Regarding Supervision of SaiLong Pharma Group Co., Ltd." from the Guangdong Securities Regulatory Bureau. Together with the Company, we conducted rectifications and proposed that the board re-deliberate and approve the "Remuneration and Senior Management Performance Management System of SaiLong Pharma Group Co., Ltd."